Company intelligence / Profile preview
AMYRA Biotech AG
Basel, Basel-Stadt, Switzerlandamyra.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Successfully completed a first-in-human clinical proof-of-principle study with lead product AMYNOPEP, demonstrating enhanced digestion of proteolytically-resistant, immunogenic gluten peptides in healthy volunteers. Results published in Frontiers in Immunology – Nutritional Immunology in October 2024[7][9]
- Therapeutic areas
- Gastroenterology
- Modalities
- Enzyme-based therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Lonza (development and manufacturing services agreement)[8]
Beyond the preview
Go deeper on AMYRA Biotech AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMYRA Biotech AG.